review article | Q7318358 |
scholarly article | Q13442814 |
P356 | DOI | 10.1097/MNH.0000000000000080 |
P698 | PubMed publication ID | 25415611 |
P2093 | author name string | Yuichi Makino | |
Masakazu Haneda | |||
Yukihiro Fujita | |||
P433 | issue | 1 | |
P304 | page(s) | 67-73 | |
P577 | publication date | 2015-01-01 | |
P1433 | published in | Current Opinion in Nephrology and Hypertension | Q15756282 |
P1476 | title | Dipeptidyl peptidase-4 inhibitors in progressive kidney disease | |
P478 | volume | 24 |
Q97523452 | Comprehensive Efficacy of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin in Practical Clinical Settings: A Prospective Multi-Center Interventional Observational Study |
Q42050075 | Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure. |
Q26739999 | Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence |
Q47215463 | Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice. |
Q38527885 | The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? |
Q88393664 | The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors |
Search more.